Influenza virus vaccine (rNA) - Protein Sciences

Drug Profile

Influenza virus vaccine (rNA) - Protein Sciences

Alternative Names: FluNhance; rNA

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator Protein Sciences Corporation
  • Developer National Institute of Allergy and Infectious Diseases; Protein Sciences Corporation
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 06 Aug 2015 Phase-II development is ongoing in USA
  • 12 Sep 2005 Profile reviewed with information available at the BIO-2005 Conference
  • 03 Dec 2001 The influenza virus vaccine is available for licensing (http://www.proteinsciences.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top